Statements (152)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:virus
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:healthcare_organization
gptkb:Magic_Johnson |
| gptkbp:advocates_for |
important for policy change
|
| gptkbp:affects |
immune system
|
| gptkbp:age |
affects all ages
|
| gptkbp:associated_with |
discrimination
stigma |
| gptkbp:campaigns |
increase awareness
|
| gptkbp:can_lead_to |
opportunistic infections
certain cancers |
| gptkbp:caused_by |
gptkb:AIDS
|
| gptkbp:clinical_trial |
ongoing for new treatments
|
| gptkbp:collaborations |
between countries
aim to reduce transmission |
| gptkbp:community_impact |
millions infected
significant public health issue significant mortality |
| gptkbp:community_involvement |
essential for education
|
| gptkbp:community_support |
crucial for affected individuals
|
| gptkbp:cultural_impact |
influence stigma
|
| gptkbp:cultural_practices |
associated with promiscuity
affects mental health associated with discrimination associated with drug use associated with homosexuality |
| gptkbp:discovered_by |
gptkb:1983
gptkb:Luc_Montagnier gptkb:Françoise_Barré-Sinoussi |
| gptkbp:disease_resistance |
achievable with treatment
|
| gptkbp:educational_programs |
target at-risk populations
|
| gptkbp:frequency |
at least once a year for high-risk individuals
recommended annually for high-risk groups every 3 months for those at high risk |
| gptkbp:gender |
prevalence varies by gender
|
| gptkbp:grooming_needs |
measured in copies per milliliter
|
| gptkbp:has_lore |
can live long with treatment
not a death sentence anymore not transmitted by casual contact |
| gptkbp:healthcare |
worldwide
disparities exist can be managed with treatment focus on prevention and treatment important for outreach part of the Sustainable Development Goals play a key role in management |
| gptkbp:historical_significance |
influenced social movements
changed public health policies led to increased funding for research affected healthcare systems impacted global health initiatives influenced healthcare access debates raised awareness of sexual health shaped community responses |
| https://www.w3.org/2000/01/rdf-schema#label |
HIV
|
| gptkbp:is_involved_in |
available for patients
|
| gptkbp:is_monitored_by |
important for tracking outbreaks
|
| gptkbp:is_popular_in |
38 million people infected
millions of people infected |
| gptkbp:is_protected_by |
gptkb:education
regular testing condom use needle exchange programs Pr EP |
| gptkbp:is_recognized_by |
gptkb:1983
in the United States |
| gptkbp:is_tested_for |
home testing kits
rapid tests home tests antibody test home testing kits available rapid tests available viral load test |
| gptkbp:is_vulnerable_to |
none available
|
| gptkbp:legal_issue |
related to discrimination
|
| gptkbp:lifespan |
improved with treatment
|
| gptkbp:manager |
necessary for health
|
| gptkbp:origin |
gptkb:simian_immunodeficiency_virus_(SIV)
likely from simian immunodeficiency virus |
| gptkbp:pharmacokinetics |
reduce viral load
|
| gptkbp:population |
growing in some regions
|
| gptkbp:provides_information_on |
varies by country
updated regularly |
| gptkbp:public_awareness |
community outreach
education programs public health campaigns important for prevention treatment access testing initiatives education on transmission |
| gptkbp:receives_funding_from |
increased over the years
global health initiatives |
| gptkbp:research |
gptkb:physicist
prevention strategies treatment advancements ongoing vaccine development functional cure studies long-acting injectable treatments |
| gptkbp:research_focus |
vaccine development
treatment advancements understanding transmission |
| gptkbp:responds_to |
gptkb:UNAIDS
funding for research WHO initiatives |
| gptkbp:scholarships |
impacted by diagnosis
|
| gptkbp:social_responsibility |
gptkb:healthcare_organization
gptkb:Hepatitis_B gptkb:Cytomegalovirus Tuberculosis blood tests opportunistic infections HIV test antibody tests viral load tests discrimination laws exist |
| gptkbp:social_structure |
affect health outcomes
|
| gptkbp:symptoms |
fatigue
fever rash swollen lymph nodes muscle aches |
| gptkbp:track_count |
indicator of immune function
|
| gptkbp:transmission |
gptkb:healthcare_organization
sexual contact blood transfusion sharing needles mother to child |
| gptkbp:treatment |
gptkb:post-exposure_prophylaxis_(PEP)
gptkb:drug improving quality of life protease inhibitors critical for effectiveness prevention of mother-to-child transmission post-exposure prophylaxis viral suppression antiretroviral drugs long-term management improved life expectancy preventing transmission integrase inhibitors long-acting injectables pre-exposure prophylaxis (Pr EP) non-nucleoside reverse transcriptase inhibitors (NNRT Is) entry inhibitors fusion inhibitors nucleoside reverse transcriptase inhibitors (NRT Is) adherence is crucial |
| gptkbp:type |
gptkb:HIV-1
gptkb:HIV-2 |
| gptkbp:type_of |
gptkb:HIV-1
gptkb:HIV-2 |